Conflict of Interest: Dr. Seng has no conflicts to report. Dr. Holroyd has received funding from the National Institutes of Health and an investigator-initiated grant from Endo Pharmaceuticals. Dr. Holroyd has full control of all primary data from the TSM trial. All analyses were conducted by Dr. Seng.
Behavioral Migraine Management Modifies Behavioral and Cognitive Coping in People With Migraine
Article first published online: 18 JUL 2014
© 2014 American Headache Society
Headache: The Journal of Head and Face Pain
Volume 54, Issue 9, pages 1470–1483, October 2014
How to Cite
Seng, E. K. and Holroyd, K. A. (2014), Behavioral Migraine Management Modifies Behavioral and Cognitive Coping in People With Migraine. Headache: The Journal of Head and Face Pain, 54: 1470–1483. doi: 10.1111/head.12426
Support for this trial was provided by grant NS-32374 (awarded to Dr. Holroyd) from the National Institutes of Health. Merck Pharmaceuticals, Inc and GlaxoSmithKline Pharmaceuticals donated triptans (5-HT1B/D-agonists) for acute migraine therapy, which was their only involvement.
- Issue published online: 16 OCT 2014
- Article first published online: 18 JUL 2014
- Manuscript Accepted: 18 JUN 2014
- National Institutes of Health. Grant Number: NS-32374
This article has been cited by: